Recombinant human endostatin
Drug timelines are a Plus or Pro feature.
11 regulatory and trial events tracked for Recombinant human endostatin, covering 2010-09-29 to 2025-07-15. Get the full timeline:
Most recent: Clinical Trial Update: Tislelizumab Combined With Recombinant Human Endostatin Combined With Chemotherapy for Unresectable Stage III Non-small Cell Lung Cancer. [Phase 2]